Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

Related Clinical Trial
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

Official Title

Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

Brief Summary

      This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with
      a long-term treatment phase.

Detailed Description

      This study is to evaluate the safety, pharmacokinetics, and efficacy of NV1205 in pediatric
      patients diagnosed with childhood cerebral adrenoleukodystrophy (CCALD).

      The study consists of:

        -  Screening period: within 30 days of first dose

        -  Main treatment period of 12 weeks (Part 1- from Screening to Week 12)

        -  Long Term Treatment (LTT) period (Part 2- Week 13 through Week 96)

      In Part 1, subjects will have an initial 4-week treatment period at the assigned dose and, if
      no safety concerns are noted, subjects continue for another 8 weeks of extended safety

      There will be several cohorts of subjects enrolled. After each Cohort has completed the
      4-week initial safety assessment, the safety data will be reviewed by an independent Data
      Safety Monitoring Board (DSMB) and, subject to DSMB recommendation, Cohort 2 will be enrolled
      and receive the next dose level. After Cohort 2 has completed 4 weeks of treatment, the DSMB
      will review all available safety data (Cohorts 1 and 2) and, subject to DSMB recommendation,
      Cohort 3 will be enrolled and receive the next dose level. Additional Cohorts may be enrolled
      at the recommendation of the DSMB with an incremental dose increase.

      In Part 2, subjects will continue to receive treatment in the LTT period of the study.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Secondary Outcome

 Area under the curve concentration of NV1205 in plasma


X-Linked Adrenoleukodystrophy


Sobetirome (NV1205)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 2018

Completion Date

December 1, 2020

Primary Completion Date

December 1, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Males ≥4 years and <18 years of age

          2. CCALD diagnosis confirmed by genetic testing

          3. Loes score of >0 and ≤15

          4. Patients on VLCFA lowering agents such as Lorenzo's oil must stop the medication and
             have high VLCFA levels before enrollment

        Exclusion Criteria:

          -  Significant medical conditions such as heart, thyroid, or liver disease

          -  HSCT recipients




4 Years - 18 Years

Accepts Healthy Volunteers



John Henderson, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

NeuroVia, Inc.

Study Sponsor

John Henderson, MD, Study Director, NeuroVia, Inc.

Verification Date

May 2018